MENA Oncology Conference
11th & 12th March 2011
Cairo, Egypt

KEY SPEAKERS AND PANELISTS

Dr. Ibthal Fadil
World Health Organization (WHO), the Regional Office for the Eastern Mediterranean EMRO, Regional Adviser

Dr. Aqeed Shaker M.
Clinic of Early Detection of Cancer, Baghdad, Director General

Dr. C S Pramesh
Tata Memorial Hospital
Therapeutic Head

Dr. Michel Daher
Lebanese Cancer Society, President

Prof. Nadia Alwan
Pioneering National Breast Cancer Research & Early Detection Program, Iraq, Executive Director

Dr. Hussein Khaled
Cairo University, Egypt
Prof. of Medical Oncology and Vice President for Postgraduate Studies and Research

Dr. Heba Sweed
Global Initiative for Breast Cancer Awareness, Egypt
Country Program Manager

Dr. Raghib Ali
INDOX Cancer Research Network, UK
Director

Dr. Andy Smith
Hologic Inc, USA, Senior Director

Nicholas Rakossy
University College London Hospital, UK
Consultant Maxillofacial/Head & Neck Surgeon

Prof. Dr. Ashraf Selim
Cairo University, Egypt
Professor of Oncology

Dr. Amin Samy Ibrahim
National Cancer Institute, Egypt
Professor of Epidemiology and Director of the National Cancer Registry of Egypt

Dr. Rabab Gasfar
NCL, Cairo University
Prof. and Head of Medical Oncology Dept.

& National Representative of

ESMO in Egypt and Africa

Dr. Oma Sialk Talaat
King Abdul Aziz Medical City, KSA
Section Head & Consultant, Dept of Oncology

Dr. Mohsen Samy Barsoun
Cairo university, Egypt
Professor of Clinical Oncology

Dr. Mohamed Shaalan
Breast Cancer Foundation of Egypt
Director

Dr. Nouran H. Said
Cairo University, Egypt
Breast Radiologist and Egyptian Society of Women’s Imaging & Health Care, Treasurer

Dr. Sanjiv Rai Jain
TAWAM Hospital, UAE
Department of Haematology and Oncology, Chairman Dr. Sid Mohamed

Dr. Anthony B. Miller
Dalla Lana School of Public Health, University of Toronto, Canada, Associate Director, Research

Dr. Carlo V. Catapano
Oncology Institute of Southern Switzerland, Switzerland
Director, Experimental Oncology

Prof. Dr. Alaa Kandil
Alexandria School of Medicine, Egypt
Professor of Clinical Oncology

Dr. Sayed A. Marid
Cairo University, Egypt, Professor of General Surgery and Head of the Breast Surgery Clinic

Chairman:

Dr. Anthony B. Miller
Dalla Lana School of Public Health, University of Toronto, Canada

Dr. David Kerr
Sidra Medical and Research Center, Qatar
Chief Research Adviser

Dr. Salwa Boudos
Galla Hospital, Egypt
Breast Radiologist

Dr. Hussein Khaled
Cairo University, Egypt
Prof. of Medical Oncology and Vice President for Postgraduate Studies and Research

Dr. Ashraf Selim
Cairo University, Egypt
Head Of Women’s Imaging Unit, Consultant of Egyptian National Breast Screening Program & President of Egyptian Society of Women’s Imaging & Health Care (ESWH)

Dr. Suad Bint Mohamed Bin Amer
King Faisal Specialist Hospital and Research Centre KSA
Head of Breast Cancer Research Unit

Zahra Breast Cancer Association, KSA
Founder and Co-Chairman

Dr. Carlo V. Catapano
Oncology Institute of Southern Switzerland, Switzerland, Director, Experimental Oncology

Dr. Raul Ribeiro
St Jude Children research hospital, USA, Director, International Outreach Program and Leukemia / Lymphoma Division

Dr. Aida Hussein, Federal Ministry of Health, Sudan, Coordinator of the Breast Cancer Control Programme

Dr. Ahmad Al Khatib
King Hussein Cancer Center, Jordan
Director of Training

Dr. Sanjay Raj Jain
TAWAM Hospital, UAE
Department of Haematology and Oncology, Chairman Dr. Sid Mohamed

Taher Alaaoui
Lalla Salma Association, Morocco
President of Scientific Committee

Dr. Anthony B. Miller
Dalla Lana School of Public Health, University of Toronto, Canada, Associate Director, Research

Dr. Carlo V. Catapano
Oncology Institute of Southern Switzerland, Switzerland
Director, Experimental Oncology

Prof. Dr. Alaa Kandil
Alexandria School of Medicine, Egypt
Professor of Clinical Oncology

Dr. Sayed A. Marid
Cairo University, Egypt, Professor of General Surgery and Head of the Breast Surgery Clinic

YOUR PRESTIGIOUS ADVISORY PANEL

Dr. Ibthal Fadil
World Health Organization (WHO), the Regional Office for the Eastern Mediterranean EMRO, Regional Adviser

Dr. Aqeed Shaker M.
Clinic of Early Detection of Cancer, Baghdad, Director General

Dr. C S Pramesh
Tata Memorial Hospital
Therapeutic Head

Dr. Michel Daher
Lebanese Cancer Society, President

Prof. Nadia Alwan
Pioneering National Breast Cancer Research & Early Detection Program, Iraq, Executive Director

Dr. Hussein Khaled
Cairo University, Egypt
Prof. of Medical Oncology and Vice President for Postgraduate Studies and Research

Dr. Heba Sweed
Global Initiative for Breast Cancer Awareness, Egypt
Country Program Manager

Dr. Raghib Ali
INDOX Cancer Research Network, UK
Director

Dr. Andy Smith
Hologic Inc, USA, Senior Director

Nicholas Rakossy
University College London Hospital, UK
Consultant Maxillofacial/Head & Neck Surgeon

Prof. Dr. Ashraf Selim
Cairo University, Egypt
Professor of Oncology

Dr. Amin Samy Ibrahim
National Cancer Institute, Egypt
Professor of Epidemiology and Director of the National Cancer Registry of Egypt

Dr. Rabab Gasfar
NCL, Cairo University
Prof. and Head of Medical Oncology Dept.

& National Representative of

ESMO in Egypt and Africa

Dr. Oma Sialk Talaat
King Abdul Aziz Medical City, KSA
Section Head & Consultant, Dept of Oncology

Dr. Mohsen Samy Barsoun
Cairo university, Egypt
Professor of Clinical Oncology

Dr. Mohamed Shaalan
Breast Cancer Foundation of Egypt
Director

Dr. Nouran H. Said
Cairo University, Egypt
Breast Radiologist and Egyptian Society of Women’s Imaging & Health Care, Treasurer

Dr. Sanjiv Rai Jain
TAWAM Hospital, UAE
Department of Haematology and Oncology, Chairman Dr. Sid Mohamed

Taher Alaaoui
Lalla Salma Association, Morocco
President of Scientific Committee

Dr. Anthony B. Miller
Dalla Lana School of Public Health, University of Toronto, Canada, Associate Director, Research

Dr. Carlo V. Catapano
Oncology Institute of Southern Switzerland, Switzerland
Director, Experimental Oncology

Prof. Dr. Alaa Kandil
Alexandria School of Medicine, Egypt
Professor of Clinical Oncology

Dr. Sayed A. Marid
Cairo University, Egypt, Professor of General Surgery and Head of the Breast Surgery Clinic

Chairman:

Dr. Anthony B. Miller
Dalla Lana School of Public Health, University of Toronto, Canada

Dr. David Kerr
Sidra Medical and Research Center, Qatar
Chief Research Adviser

Dr. Salwa Boudos
Galla Hospital, Egypt
Breast Radiologist

Dr. Hussein Khaled
Cairo University, Egypt
Prof. of Medical Oncology and Vice President for Postgraduate Studies and Research

Dr. Ashraf Selim
Cairo University, Egypt
Head Of Women’s Imaging Unit, Consultant of Egyptian National Breast Screening Program & President of Egyptian Society of Women’s Imaging & Health Care (ESWH)

Dr. Suad Bint Mohamed Bin Amer
King Faisal Specialist Hospital and Research Centre KSA
Head of Breast Cancer Research Unit

Zahra Breast Cancer Association, KSA
Founder and Co-Chairman

Dr. Carlo V. Catapano
Oncology Institute of Southern Switzerland, Switzerland, Director, Experimental Oncology

Dr. Raul Ribeiro
St Jude Children research hospital, USA, Director, International Outreach Program and Leukemia / Lymphoma Division

Dr. Aida Hussein, Federal Ministry of Health, Sudan, Coordinator of the Breast Cancer Control Programme

Dr. Ahmad Al Khatib
King Hussein Cancer Center, Jordan
Director of Training

EVENT OVERVIEW

Cancer is a major public health problem that affects every country in the MENA (Middle East & North Africa) region regardless of economic and social situation and this Conference will focus mainly on the Breast Cancer as it is the most common type of cancer in this region.

This conference will also include new information, consolidated knowledge, and conversations on controversial issues regarding Prevention & Risk of cancer, Imaging & Screening, new approaches in targeted therapies, and more.

MENA Oncology Conference will be a great opportunity for governmental and non-governmental cancer control officials; for physicians, researchers and health professionals; and also for patients, advocates, volunteers and others interested in cancer control, from all over the world, to get together and exchange views on how to deal with cancer.

WHO WILL ATTEND?

• Governmental and non-governmental cancer control officials

• Medical, surgical, and radiation oncologists, haematologists and pathologists interested in the treatment of patients with Breast cancer

• Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of cancer are also invited to attend.

visit our website:
www.fleminggulf.com

Bronze Sponsor

Associate sponsor:

Supporting associations:

Strategic Partner:

Media Partners:
Day 1 | 11th March 2011

8:00 Registration and Coffee

9:00 Opening remarks from the chair
Co-Chairman: Dr Andy Smith, Hologic Inc, USA
Senior Director

Regional Perspective on Breast Cancer

9:10 KEYNOTE Breast Cancer in Eastern Mediterranean Region & WHO strategic interventions
• Current Situation of Breast Cancer in the MENA region.
• WHO Strategic intervention to control cancer

Dr Ibtihal Fadhil, World Health Organization (WHO)
The Regional Office for The Eastern Mediterranean EMRO, Regional Adviser

9:30 Introducing a Comprehensive Information System on Breast Cancer Control in the Eastern Mediterranean Region
• Apart from being the commonest cancer among women in countries within the Eastern Mediterranean Regions (EMR), there are other factors that justify increasing efforts for breast cancer control. These include younger ages at presentation, late stages at first diagnosis and the prevalence of more aggressive tumour behavioural forms.
• High mortality/ incidence ratio is a usual finding in those countries. Most of the national cancer registries in the EMR lack data regarding age-specific incidence rates, stage of disease at presentation and survival rates.
• A comprehensive database breast cancer information system was designed under supervision of IARC (International Agency for Research on Cancer) to compare the demographic characteristics, clinicopathological presentations and treatment outcomes of breast cancer patients within selected countries in the Middle East including Iraq, Jordan, Lebanon and Egypt

Prof. Nada Alwan, Pioneering National Breast Cancer Research & Early Detection Program, Iraq, Executive Director

9:50 The Challenges facing national cancer control plans (Egypt Case)
• Causes of The Growing Cancer burden
• Challenges facing the Cancer control plans
• Local strategies to overcome these Challenges

Dr Amal Samy Ibrahim
National Cancer Institute, Egypt
Professor of Epidemiology

10:30 Morning Coffee and Networking

Breast Cancer

11:00 The Global Initiative for Breast Cancer Awareness in Egypt, Relation between awareness and early detection of breast cancer
Dr. Heba Sweed, Global Initiative for Breast Cancer Awareness, Egypt, Country Program Manager

11:40 Optimizing Endocrine Therapy for Indolent Breast cancer
• In Premenopausal women
• In Postmenopausal
• Preoperative Endocrine therapy

Dr. Hussein Khaled, Cairo University, Egypt
Prof. of Medical Oncology and Vice President for Postgraduate Studies and Research

12:20 Controversies in Neoadjuvant Therapy
• Radiation after Breast Conserving surgery
• Impact of systemic Therapy
• Postmastectomy radiation in 1-3 positive nodes

Dr Rabab Gaafar, NCI, Cairo University, Prof and Head of Medical Oncology Dept & National Representative of ESMO in Egypt and Africa

13:00 Friday’s Prayer and Lunch

14:30 The Moroccan (Lalla Salma) program in early detection and screening for Breast Cancer
• Primary health care system: screening
• Secondary health care system: diagnosis
• Tertiary health care system: treatment

Dr Sidi Mohamed Taher Alaoui
Lalla Salma Association, Morocco
President of scientific Committee

15:10 Screening for breast cancer - different approaches
• Effects of mammography screening under different scheduling:
  Estimates of potential benefits and harms
  Evidence on other screening modalities, CBE and BSE

Dr Anthony B. Miller, Dalla Lana School of Public Health, University of Toronto, Canada
Associate Director, Research

15:50 Afternoon tea and networking

16:20 Magnetic Resonance Imaging MRI of the Breast, when and why?
Magnetic Resonance Imaging (MRI) is a noninvasive procedure, which represents the most sensitive modality for the detection of invasive breast cancer in high risk patients. It is a powerful tool in diagnosing multifocality, or multicentricity, as well as contralateral malignant foci. It can also help assess for residual invasive cancer in patients who have undergone lumpectomy with positive margins at pathology. In assessment of the post operative breast, it has proved reliability in differentiating scar tissue from recurrence, and has proved to be the gold standard in evaluation of silicone implant integrity. However, it is a problem solving tool and should not replace standard screening and diagnostic procedures.

Dr Norran H. Said, Cairo University, Egypt
Breast Radiologist and Egyptian Society of Women’s Imaging & Health Care, Treasurer

17:00 Interactive Panel Discussion: Are we over treating small screening detected Breast Cancers?
• Earlier diagnosis creates a new situation in which both the diagnostic and the therapeutic team members encounter previously uncommon situations.
• Guidelines for the treatment of small non palpable breast cancers should not be based on trial results obtained from palpable, clinically diagnosed cancers.
• Using the established methods for treating mammographically detected palpable cancers, non-palpable lesions carry a considerable risk of over treatment, because the histologic prognostic parameters do not reliably predict the outcome of 1-14 mm invasive breast cancers

Moderator:
Prof Dr Ashraf Selim, Cairo University, Egypt
Professor Of Oncology

Panellists: Dr Mohamed Shaalan
Breast Cancer Foundation of Egypt, Director

Dr. Sayed A Marei, Cairo University, Egypt
Professor of General Surgery and Head of the Breast Surgery Clinic

Dr. Anael Shaker M., Clinic of Early Detection of Cancer, Baghdad, Director General

Dr. Mohsen Samy Barsoum, Cairo university, Egypt
Professor of Clinical Oncology

17:40 Networking Reception and close of Day 1
Day 2 | 12th March 2011

8:00 Registration and Coffee

9:00 Opening remarks from the chair
  Co-Chairman: Dr Andy Smith, Hologic Inc, USA
  Senior Director

Head and Neck Cancer

9:10 Comprehensive Surgical Management of the Head & Neck Cancer Patient
  - Exposure to modern methods of surgical management of Head & Neck cancer
  - Reconstructive challenges faced for the H & N cancer patient
  - Future perspectives in the surgical treatment of the Head & Neck
  Nicholas Kalavrezos
  University College London Hospital, UK
  Consultant Maxillofacial/Head & Neck Surgeon

9:50 Emerging Concepts in Head and Neck Cancer diagnostics and Therapy
  - Biomarkers in molecular classification and diagnostics of head and neck cancer
  - Molecularly targeted therapies in thyroid cancer

10:30 Morning Coffee and Networking

11:00 Microvascular free tissue transfer, a unique niche for plastic surgeons in head and neck cancer care
  - The proven reliability of free-tissue transfer
  - Minimization of the morbidity in reconstruction of major head and neck defects.

Cancer Research

11:40 Establishing a Clinical Research Network across the MENA region
  - Clinical research is a critical tool in the fight against cancer as it does not only help to identify the best treatment for individual cancer patients, but also helps governments and agencies develop appropriate plans and long-term strategies for cancer control and prevention.
  - The MENA region has well-trained physicians, scientists and well-equipped hospitals in but very limited experience in clinical research. A cooperative group that facilitates collaborative research through providing a platform of action and expertise is needed.
  - A Cancer Research Network will therefore be established across the MENA region which will conduct research, training, education, and facilitate collaboration, thereby becoming a regional leader and a major global contributor to oncology research.
  Dr Raghib Ali, INDOX Cancer Research Network, UK
  Director

12:20 Lunch Break

13:50 Ethics of Biomedical Research on Human Subject
  Scientific research is the systematic collection, analysis and interpretation of data to respond to human curiosity, and answer a certain question or solve a problem. Medical research can be defined as the application of the scientific method to medicine, and because it involves human subjects, it raises complex ethical, legal and social issues. The ethical and scientific standards for carrying such a research on human subjects have been developed and established in international guidelines, including the Declaration of Helsinki, the CIOMS International Ethical Guidelines for Biomedical Research Involving Human Subjects, and the WHO Guidelines for Good Clinical Practice. Researchers have a responsibility to inform themselves about the ethical, legal and policy standards that govern their activities. Compliance with these guidelines helps to ensure that the dignity, rights, safety, and well-being of research participants are promoted and that the results of the investigations are credible.
  Dr Michel Daher, Lebanese Cancer Society, President

14:30 Therapeutic strategies to target cancer stem cells and metastasis
  New concepts are challenging our views of critical aspects of tumor biology. Recent research has highlighted the importance of tumor heterogeneity and tumor-initiating cells with stem cell-like properties in tumor initiation and progression. Multiple genetic and epigenetic factors control normal and cancer stem cell biology and are at play in the metastatic cascade. As the pathways involved in these processes are progressively unraveled, new therapeutic targets and strategies will become available for devising more effective treatments for cancer. Although we are still at the early stages of translating these new findings into clinical applications, the initial results are encouraging. We will review the most recent findings on the critical pathways and therapeutic strategies under development.
  Dr Carlo V. Catapano
  Oncology Institute of Southern Switzerland, Switzerland, Director, Experimental Oncology

15:10 Afternoon Tea

15:40 Screening for lung cancer - magic grail or mere hype
  Dr C S Pramesh, Tata Memorial Hospital
  Thoracic Surgery Head

16:20 Gene Promoter Methylation as a Biomarker to Assess Selenium Chemoprevention for lung cancer
  - Gene promoter methylation in biological fluids is emerging as a biomarker that could be important for early detection of lung cancer and monitoring prevention and intervention.
  - The prevalence of methylation of multiple gene promoters was evaluated in sputum and plasma from women at different risk for lung cancer.
  - Lung cancer survivors participating in the selenium chemoprevention trial showed the highest prevalence for methylation in sputum and plasma compared to cancer-free smokers and never smokers.
  - Sputum was superior for classifying methylation status of genes in tumor biopsies with a positive predictive value of 86% for the combined effect of four genes.

17:00 Interactive Panel Discussion: Nicotine, Tobacco and Cancer Control
  - Health consequences of smoking
  - Tobacco free initiatives
  - Anti tobacco campaigns

17:40 Closing Remarks from the Chair
  I would like to thank everyone who has helped with the research and organization of this event, especially the advisors for their support and commitment.
  Doaa Said, doaa.said@fleminggulf.com

email: tarun.rajagopal@fleminggulf.com, www.fleminggulf.com
Meet Our Speakers

Dr Ishithal Fadhill, World Health Organization (WHO)
The Regional Office for the Eastern Mediterranean, Regional Adviser

Dr Ishithal Fadhill is Regional Adviser for Non communicable Diseases at Eastern Mediterranean Regional Office since June 2008. Dr Fadhill graduated in Medicine from Basra College of Medicine. She obtained her past graduate qualifications (MSc, PhD, Diploma) in United Kingdom, Lebanon, Jordan, Egypt and Tropical Medicine, in 1981, 1987 and 2003 in NZREX clinical examination at the New Zealand Medical Council, Auckland, New Zealand. Prior to joining WHO, Dr Fadhill held several positions in clinical and academic medicine in different countries. In Iraq, during the period (1978-1991) Dr Fadhill worked as a research fellow and deputies in many academic and clinical positions. During this period she received her M.B.N. from the University of Basra, Iraq. Currently, Dr. Fadhill serves as WHO project manager in Southern Iraq. From the period (1991-1995) Dr. Fadhill appointed as Assistant Professor, Faculty of Medicine, University of Jordan, Amman, Jordan. In 1995 Dr. Fadhill moved to New Zealand and appointed as Leader for the Post graduate programs, Health Studies Department, Manukau Institute of Technology, Auckland, New Zealand,(1995-2002), During this period she joined EMRO as Short-term professional in NCD Unit. From the period 2001 to 2005 she was working asön assistant professor, Faculty of Medicine, University of Jordan, Amman, Jordan. And she was appointed as the assistant professor, Faculty of Medicine, University of Baghdad, Iraq, since 2006. Dr Fadhill holds several committee membership and services and she is the author of many publications in different topics and fields of expertise which were published in many medical association journals.

Dr Anthony B. Miller, Dalla Lana School of Public Health, University of Toronto, Canada, Associate Director, Research

Professor Emeritus and Associate Director, Research, Dalla Lana School of Public Health, University of Toronto, Dr. Miller is a consultant to the Division of Cancer Prevention US National Cancer Institute and to the World Health Organization, is Co-Chair of the Cancer Risk Management Steering Committee and a member of the Action Council, Canadian Partnership against Cancer. He qualified in Medicine in 1955, was a member of the scientific staff of the UK Medical Research Council, 1962-71, Director of the Epidemiology Unit of the National Cancer Institute of Canada 1971-86, Chair of the Department of Preventive Medicine and Biostatistics, University of Toronto, 1979-86, special advisor to the Division of Cancer Prevention, US National Cancer Institute, 1997, Senior Epidemiologist, International Agency for Research on Cancer 1998-9 and Head, Division of Cancer Epidemiology, Deutsches Krebsforschungszentrum, Heidelberg, 2000-3. His research encompasses cancer control, prevention and screening.

Dr Rabab Gaafar, NCI, Cairo University

Prof and Head of Medical Oncology Dept & National Representative of ESMO in Egypt and Africa

Dr. Rabab Gaafar received her M.B.B.Ch. from Faculty of Medicine, Cairo University, M. S. General Medicine from Faculty of Medicine, Cairo University, and M.D. certification in medical Oncology from the National Cancer Institute, Cairo University. Prof. Rabab Gaafar is directing the Thoracic Oncology Program at NCI, Cairo and she is also heading the Early Detection Prevention Unit at the same hospital. She is currently Chairman of quality assurance on the Board of the European Organization for Research and Treatment of Cancer Lung Croup (EORTC). Prof. Rabab Gaafar has published more than 150 publications in National and international journals and was invited speaker in the journal of the National Cancer Institute, Cairo. In (2007) and (2008), she received an Award for distinguished publications in international peer-reviewed journals. She also had received previously the Medical Syndicate Award of Cairo University in 2002, 2006, 2009 and 2011. She was awarded the Cairo University Award of appreciation for excellence. Prof. Rabab Gaafar holds memberships in several professional Societies including the International Association for the Study of Lung Cancer (IASLC) and the International Medical Oncology Society (IMOS), International Network for Cancer Treatment and Research (INCTR), Egyptian Cancer Society and Board member of Arab Medical Association and Egyptian Foundation for research of Cancer, and is also the founder and director of the Cairo Oncology School. As of January 2008, she is now the regional representative for Egypt and North Africa for the European Society of Medical Oncology (ESMO). Recently, she is National representative for Egypt in the Mediterranean Multidisciplinary Oncology Forum (MMFO). Prof. Rabab Gaafar is mainly interested in solid tumors mainly Lung Cancer, Mesothelioma, and Breast Cancer, targeted therapy and new drugs.

Prof. Nada Alwan, Pioneering National Breast Cancer Research & Early Detection Program, Iraq, Executive Director

As a Professor of Pathology, directing the Breast and Cervical Cancer Research Unit (Baghdad University Medical College/Medihan) and the Main Referral Training Center for Early Detection of Breast Tumours (Medical City Teaching Hospital/MOH), Dr Alwan devoted her scientific efforts and clinical practice to early detection and screening for breast cancer in Iraq. Together with other colleagues and in collaboration with WHO, Dr. Nada Alwan organized the National Program for Early Breast and Cervical Cancer Detection Project in Baghdad in Iraq (MCI-2001). Since then, specialized centers and clinics for early detection of breast cancer were established all over the 18 Iraqi Governorates. She supervised several national and international training courses focusing on the implementation of the WHO Early Breast Cancer Detection Project. In 2005, she established the first center of excellence for breast cancer at the faculty of Medicine at Baghdad University and the National Breast Cancer Registry of Iraq. As of January 2008, she is now the Regional Representative for Iraq and North Africa for the European Society of Medical Oncology (ESMO). Recently, she is National representative for Egypt in the Mediterranean Multidisciplinary Oncology Forum (MMFO). Prof. Rabab Gaafar is mainly interested in solid tumors mainly Lung Cancer, Mesothelioma, and Breast Cancer, targeted therapy and new drugs.

Dr Hussein Khaled, Cairo University, Egypt

Prof. of Medical Oncology and Vice President for Postgraduate Studies and Research

Professor of Medical Oncology and the previous Dean of the National Cancer Institute, Cairo University. He is currently the Vice President of Cairo University for Graduate Studies and Research. Prior to that position, he was professor and Head of Medical Oncology Dept & National Representative of ESMO in Egypt and Africa from 2008 to 2011. He was the Chief of Medical Oncology Unit at the National Cancer Institute in Cairo from 2001 to 2011. Dr. Khaled graduated from the faculty of Medicine at Cairo University. His areas of expertise include medical Oncology, Clinical Trials and Management of Bilharzial related bladder cancer, non-Hodgkin’s lymphomas, and breast cancer. He is the editor on a book on lymphomas, Nutrition and Cancer (in Arabic), and associate editor on a book on Breast Cancer.In addition to the latest international data and information, these books include as well all relevant local Egyptian experience and results of most of their important clinical trials. Dr. Khaled is also the founder and head of the PhD program in medical Oncology at the National Cancer Institute. He is the Head of the Scientific Council of the East Mediterranean Oncology region against Breast cancer. He has published over 110 papers, and 60 abstracts in both national and international journals, and conferences. The main research interest is in the Clinico-biologic characteristics and management of Bilharzial related bladder cancer, non-Hodgkin’s lymphomas, and breast cancer. He is theeditor on a book on lymphomas, Nutrition and Cancer (in Arabic), and associate editor on a book on Breast Cancer.In addition to the latest international data and information, these books include as well all relevant local Egyptian experience and results of most of their important clinical trials. Dr. Khaled is also the founder and head of the PhD program in medical Oncology at the National Cancer Institute.

Dr Sayed A Marei, Cairo University, Egypt

Professor of General Surgery and Head of the Breast Surgery Clinic

Dr. Sayed A Marei is a Professor of General Surgery at El Ain Medical School Cairo University. He obtained his M.D degree in Gen Surgery in 1985. He is currently the head of the surgical breast clinic in the general surgery department Kasr El Aini Medical School. His previous main interest was in oesophagus and oesophago-gastric surgery. His main current interest for the last few years has been the initiation and maintenance of a multidisciplinary breast clinic as well as the supervision of research in the domain of surgery of breast cancer and oncoplastic techniques. He has been offering its free surgical service which includes breast reconstruction for breast cancer patients.

Dr C S Premesh, Tata Memorial Hospital, Thoracic Surgery Head

Dr Premesh is an Associate professor and head, Thoracic Surgery at Tata Memorial Hospital. He is a member of the TMC Research Administrative Council and the hospital scientific review committee. His clinical interests include esophageal and lung cancer and minimal invasive thorascoscopy and laparoscopy in the treatment of these cancers. He has had extensive training in clinical research methodology, biostatistics and bioinformatics. His research interests are widespread and span areas of cancer epidemiology, clinical and translational research. He is a principal investigator in several investigator initiated and industry sponsored clinical trials in thoracic oncology. He has over 80 peer reviewed journal publications and chapters in text books. The Clinical Research Secretariat, which he heads, has the stated mandate of facilitating and supervising a strong investigator-initiated research capacity in the hospital. He is also the convener and principal investigator of an annual meeting on Evidence Based Management of common cancers which has been held for the past eight years at the centre. He is keenly interested in training investigators in clinical research and organizes workshops and short courses on clinical research methodology and Good Clinical Practice. He is a regular speaker in meetings and workshops on clinical research methodology and biostatistics. He is an expert reviewer for several national and international journals in surgery, thoracic surgery and oncology.

Prof Dr Alaa Kandil, Alexandria School of Medicine,Egypt

Professor of Scientific Research

Alaa Kandil has started his oncology profession 1982 where he was appointed as a full time resident in the department of Clinical Oncology & Nuclear medicine after which he obtained his Master degree (general Grade, Excellent). His training included dealing with all types of malignancies with radiation and medical oncology programs. Shortly after, he had a 3 months training at ST Luke’s, Hospital, Guiford and the Royal Manohan Hospital, London, England. From 1989, Dr kandil went to Stanford university, California, USA where he had his Doctorate degree thesis done and his thesis (drug resistance, interaction between chemotherapy and...
& hyperthermia) was defended back home in 1991 and he passed his exams to obtain his Doctorate degree and been appointed as a lecturer in his University, 1993. Dr Kandil joined the Head and Neck Surgical Oncology team at the King Faisal Specialist Hospital (Tertiary Care Center), Riyadh, Saudi Arabia for 8.5 years. Dr Kandil is full professor at the department of Clinical Oncology & Nuclear Medicine, Alexandria School of Medicine (2003 till present). Dr Kandil has over 20 publications in international journals and a great deal of experience in managing malignancies of the breast, head & neck, lymphomas and gynecological malignancies.

Dr. Carlo V. Catapano, Institute of Southern Switzerland, Switzerland
Director, Lab of Experimental Oncology

Carlo V. Catapano, MD, PhD, Director, Laboratory of Experimental Oncology, Oncology Institute of Southern Switzerland (IOSI), received the MD degree in 1983 from the University of Naples, Italy. From 1983 to 1988 he was a resident in the Medical Oncology Division at the University of Naples and a fellow in Cancer Pharmacology at the “Mario Negri” Institute for Pharmacological Research in Milan, Italy. From 1988 to 1993 he worked in the Wake Forest University Comprehensive Cancer Center in Winston-Salem, NC, USA, where he received the PhD in Biochemistry. In 1993 he moved to the Medical University of South Carolina (MUSC) in Charleston, SC, USA, where he held faculty appointments in the Departments of Experimental Oncology, Biochemistry and Molecular Biology, and Medicine/Division of Hematology/Oncology. He was senior investigator at the Hollings Cancer Center, the Center for Molecular and Structural Biology, and the Laboratory of Cancer Genomic of the MUSC. Since 2003 he is the Director of the research laboratories of the IOSI in Bellinzona, Switzerland. His research interests are in the field of experimental therapeutics, molecular pharmacology, development of molecular- and gene-targeted therapeutics, transcription factors and epigenetic mechanisms along with translational and clinical studies on new anticancer agents.

Dr. Omalkhair Abulkhair, King Abdul Aziz Medical city, KSA
Section Head & Consultant, Dept of Oncology

Dr. Omalkhair Abulkhair is currently the Section Head of the Division of Adult Medical Oncology, Department of Oncology in King Abdulaziz Medical City – Riyadh, Kingdom of Saudi Arabia and Assistant Professor in King Saud bin Abdulaziz University for Health Sciences. Being one of the renowned oncologists in the Middle East, she was nominated to be part of the Women in High Places: Fight against Cancer, an international organization of prominent women in their respective areas. She is the Course Director of major symposia and conferences in the department such as the Best of CTRC-AACR San Antonio Breast Cancer Symposium and Cancer Prevention and Early Detection Symposium. She was also selected as the Chairman for MENA-NCCN Guidelines Committee for Breast Cancer. This committee aims to update the guidelines for breast cancer management in the region. Furthermore, Dr. Abulkhair was also chosen to lead the National Committee for Breast Cancer by the Ministry of Health in Riyadh.

Dr. Mohsen Samy Barsoum, Cairo university, Egypt
Professor of Clinical Oncology

Doctorate degree clinical oncology, Cairo university 1977 - Professor of clinical oncology NCI Cairo university. ASCO, ESMO ASRO, ESTR0 Member and Egyptian society of oncology.

Dr. Heba Sweed, Global Initiative for Breast Cancer Awareness, Egypt
Country Program Manager

Dr. Heba Sweed is the Program Manager of the Global Initiative for Breast Cancer Awareness in Egypt. She is a qualified physician with 10 years experience in the medical field, including a managerial position in a multinational pharmaceutical company developing and managing patients and healthcare providers’ educational programs. She most recently held the position of Quality Improvement Specialist for a project focusing on integrating maternal and child health at all levels. As part of her MBA, Dr. Sweed focused her thesis on exploring and identifying the needs of communities in rural areas, and building the capacity of small NGOs to develop, manage and promote micro-health insurance schemes for these communities based on their needs.

Dr. Norran H. Said, Cairo university, Egypt
Breast Radiologist, Egyptian Society of Women Imaging & Health Care, Treasurer

Dr. Norran H. Said is a dedicated breast imaging radiologist at Cairo University Hospital, and Cairo Radiology Center (Cairo Scan). She is also an active breast screening radiologist at the Egyptian National Breast screening Program, known as the Women’s Health Outreach Program. More over, she is a founding member and treasurer of the Egyptian Society of Women’s Imaging & Health Care, as well as the National Foundation for Breast Cancer Elimination. Her main field of interest & research is Breast MRI.

Dr. Ashraf Selim, Cairo university, Egypt, Professor of Oncology

Dr Asfraf Selim is a professor of radiology at Cairo University, and head of the women’s imaging unit. Moreover, he is a consultant at the Egyptian National Breast screening program, and Executive Manager of Cairo Scan, the largest radiological private center in Egypt. As an enthusiast on breast imaging, he was one of the first to implement it and has presented & published several related studies. In 2005, he became the President & founder of the Egyptian Society of Women’s Imaging & Health Care, which organizes annual workshops to upgrade radiologists on breast screening and diagnostic techniques.

Nicholas Kalavrezos, University College London Hospital, UK
Consultant Maxillofacial/Head & Neck Surgeon

Nicholas was appointed Consultant Maxillofacial/Head & Neck Reconstructive Surgeon at UCH in 2002. Mr Kalavrezos has a sub-speciality interest in facial and oral oncology and microvascular reconstruction. His main clinical research interests are the diagnostic and therapeutic aspects in the management of advanced head and neck cancer, and the functional and aesthetic rehabilitation of the head and neck with flap reconstruction. He provides the surgical treatment for the Head & Neck Sarcomas as the Lead Head & Neck Surgeon of the London Sarcoma Centre based at UCH. His research interests include tissue engineering for complex facial defects and robotic surgery for inaccessible areas of the head and neck.

Dr. Raghib Ali, INDOX Cancer Research Network, UK, Director

Dr Raghib Ali is the Director of the INDOX Cancer Research Network, India’s largest academic oncology network, which he has led since its establishment in 2005 and a Clinical Epidemiologist at the Cancer Epidemiology Unit at the University of Oxford. He is also a Honorary Lecturer in Clinical Pharmacology, an Honorary Consultant in Acute Medicine at the John Radcliffe Hospital in Oxford and the Richard Doll Medical Tutorial Fellow at Green-Templeton College. His main research interests are the aetiology, prevention & treatment of cancer in South Asian and Middle Eastern populations. He graduated from Cambridge University in 1999 with a distinction in Medicine and was awarded the John Addenbrook prize for Medicine for the best performance throughout medical school.

Meet Our Sponsors

Hologic:
Preserving the Gifts of Wellness and Life.

At Hologic our focus is women’s health. Our mission is to Provide Leading Edge Technologies Targeting Women’s Health with an Emphasis on the Early Detection of Diseases – Ultimately Saving Lives. Our passion can be seen in our innovative diagnostic imaging systems for the early detection of breast cancer and osteoporosis assessment, in addition to our innovative and effective technologies in early detection of cancer cervix and treatment of menopause. We strive to continually push the boundaries of imaging to provide you with superior image quality and diagnostic accuracy. Every year, Hologic spends tens of millions of dollars in research and development to advance the field of women’s healthcare. As our clinical areas expand, we are taking on a broader range of health issues, yet our goal remains the same: to deliver innovative technologies that result in better outcomes for women. Working together we cannot fail.

SupeSonic:

SuperSonic Imagine is an innovative corporation that was founded in 2005 by experts in the ultrasound medical imaging field. SuperSonic Imagine has created a revolutionary ultrasound system named the Axiplorer®, with an all software-based architecture that allows for great speed, accuracy and flexibility. Only SonicSoftware™ supports a new dimension in ultrasound: MultiWave™ Technology, two waves to better characterize tissue. This technology ensures impeccable images from an ultrasonic wave and real-time, local tissue elasticity values in kilopascals from a shear wave, ShearWave Elastography™. The Axiplorer gives physicians the added diagnostic confidence they require.
Sales Contract

Please complete this form and fax back to
+ 91 80 3991 9099
or email to: tarun.rajagopal@fleminggulf.com

Registration Details

☑ Ms ☐ Mrs ☐ Mr Surname: __________________________
Name: __________________________
Job Title: __________________________
Email: __________________________

☑ Ms ☐ Mrs ☐ Mr Surname: __________________________
Name: __________________________
Job Title: __________________________
Email: __________________________

☑ Ms ☐ Mrs ☐ Mr Surname: __________________________
Name: __________________________
Job Title: __________________________
Email: __________________________

Organisation: __________________________
Contact person: __________________________
Email: __________________________
City: __________________________
Country: __________________________
Phone: __________________________
Fax: __________________________
Address: __________________________
Nature of business: __________________________
Website: __________________________

Payment Method

Please debit my
Visa ☐ Eurocard/Mastercard ☐ Amex ☐ Diners club ☐

Card Billing Address:
Street: __________________________
City: __________________________
Post/Zip Code __________________________
Card Holder’s name: __________________________
Card Holder’s Signature: __________________________
Card Number: __________________________
Visa CVC Number or Eurocard/Mastercard CVV Number __________________________
(last 3 digits on the back on the card) __________________________
Valid from __________________________/ __________________________
Expiry Date __________________________/ __________________________

I agree to Fleming Gulf terms and Conditions and Fleming Gulf debiting my card.

Authorization

Signatory must be authorized on behalf of contracting organisation
Name: __________________________
Date: __________________________
Signature: __________________________
Booking is invalid without a signature

Fleming Gulf

2 Days Conference ☐ ☐ $ 500 per delegate

Discounted Price ☐ ☐ $ 300 per delegate

Terms and Conditions:

Fleming Gulf requires the full payment within 5 days from receipt of invoice. Fleming Gulf reserves the right to refuse entry to any customer who has not paid their invoice. A credit card guarantee may be requested if full payment has not been received. All bookings carry a 50% liability after the booking has been made. There will be no refunds for cancellations received on or after one month before the start of the conference. If you decide to cancel after this date the full invoice remains payable.

Fleming Gulf reserves the right to change the content, timing, speakers or venue should circumstances require. The event may be postponed or cancelled due to acts of terrorism, war, extreme weather conditions, industrial action, acts of God or any event beyond the control of Fleming Gulf. If such a situation arises we will endeavour to reschedule the event. However, Fleming Gulf cannot be held responsible for any cost, damage or expenses which may be incurred by the customer as a consequence of the event being postponed or cancelled. Fee does not include travel, hotel accommodation, transfers or insurance.

Fee includes:

☑ Documentation Pack
☑ Course Sessions
☑ Lunches and refreshments

Hotel Accommodation:
Overnight accommodation is not included in the registration fee. A reduced rate will be available at the Conference Hotel. Booking form will be sent out right after the venue will be confirmed, but not later than one month prior to the event.